Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies

Archives of Gynecology and Obstetrics

Volumn 292, Issue 3, 2015, Pages 507-518

  Liu, Yuxiu ^a   Zhao, Yang ^a   Yu, Ailing ^b   Zhao, Bin ^a   Gao, Yufang ^a   Niu, Haitao ^a  

^a QINGDAO UNIVERSITY   (China)

^b Weifang Maternal and Children Hospital ^*  (China)

Author keywords

Meta analysis; Placental growth factor; Preeclampsia; sFlt 1 PlGF ratio; Soluble Fms like tyrosine kinase 1

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN; SIGNAL PEPTIDE;

DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GESTATIONAL AGE; HUMAN; META ANALYSIS; PREDICTIVE VALUE; PREECLAMPSIA; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ADULT; BLOOD; FEMALE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION;

ADULT; BIOMARKERS; FEMALE; GESTATIONAL AGE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY PROTEINS; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84938743529     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-015-3671-8     Document Type: Review

References (42)

1. Schoofs K, Grittner U, Engels T, Pape J, Denk B, Henrich W, Verlohren S (2014) The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med 42(1):61–68
2. Mackay AP, Berg C, Atrash H (2001) Pregnancy-Related Mortality From Preeclampsia and Eclampsia. Obstet Gynecol 97(4):533–538
3. Powe CE, Levine RJ, Karumanchi SA (2011) Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123(24):2856–2869. doi:10.1161/CIRCULATIONAHA.109.853127
4. Kar M (2014) Role of biomarkers in early detection of preeclampsia. J Clin Diagnostic Res 8(4):BE01-BE04
5. Cerdeira AS, Karumanchi SA (2012) Angiogenic factors in preeclampsia and related disorders. Cold Spring Harbor perspectives in medicine. doi:10.1101/cshperspect.a006585
6. Rana S, Karumanchi SA, Lindheimer MD (2014) Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension 63(2):198–202. doi:10.1161/hypertensionaha.113.02293
7. Widmer M, Villar J, Benigni A, Conde-Agudelo A, Karumanchi SA, Lindheimer M (2007) Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol 109(1):168–180. doi:10.1097/01.AOG.0000249609.04831.7c
8. Kleinrouweler CE, Wiegerinck MMJ, Ris-Stalpers C, Bossuyt PMM, Van Der Post JAM, Von Dadelszen P, Mol BWJ, Pajkrt E (2012) Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG Int J Obstet Gynaecol 119(7):778–787
9. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, vol 339. doi:10.1136/bmj.b2535
10. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MMG, Sterne JAC, Bossuyt PMM (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536. doi:10.7326/0003-4819-155-8-201110180-00009
11. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH (2005) Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58(10):982–990. doi:10.1016/j.jclinepi.2005.02.022
12. Hellmich M, Lehmacher W (2005) A Ruler for interpreting diagnostic test results 44(1):126
13. Kim SY, Ryu HM, Yang JH, Kim MY, Han JY, Kim JO, Chung JH, Park SY, Lee MH, Kim DJ (2007) Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci 22(5):873–877
14. Stepan H, Unversucht A, Wessel N, Faber R (2007) Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 49(4):818–824. doi:10.1161/01.HYP.0000258404.21552.a3
15. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D’Anna R (2008) Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 87(8):837–842. doi:10.1080/00016340802253759
16. Diab AE, El-Behery MM, Ebrahiem MA, Shehata AE (2008) Angiogenic factors for the prediction of pre-eclampsia in women with abnormal midtrimester uterine artery Doppler velocimetry. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet 102(2):146–151. doi:10.1016/j.ijgo.2008.02.016
17. Sibai BM, Koch MA, Freire S, Pinto e Silva JL, Rudge MV, Martins-Costa S, Bartz J, de Barros Santos C, Cecatti JG, Costa R, Ramos JG, Spinnato JA 2nd (2008) Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol 199(3):268.e261–e269. doi:10.1016/j.ajog.2008.06.071
18. Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS, Gomez R, Yeo L, Conde-Agudelo A, Hassan SS (2009) A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Mater-Fetal Neonatal Med Off J Euro Assoc Perinatal Med Fed Asia Oceania Perinatal Soc Int Soc Perinatal Obstet 22(11):1021–1038. doi:10.3109/14767050902994754
19. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigo J Jr (2010) Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertension research Off J Japan Soc Hypert 33(9):892–898. doi:10.1038/hr.2010.92
20. Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, Suzuki M (2010) Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypert Res Off J Japan Soc Hypert 33(5):422–427. doi:10.1038/hr.2010.15
21. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H (2010) An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. American journal of obstetrics and gynecology 202(2):161.e161–161.e111. doi:10.1016/j.ajog.2009.09.016
22. McElrath TF, Lim KH, Pare E, Rich-Edwards J, Pucci D, Troisi R, Parry S (2012) Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. American journal of obstetrics and gynecology 207(5):407.e401–407.e407. doi:10.1016/j.ajog.2012.08.010
23. Chen G, Zhang L, Jin X, Zhou Y, Niu J, Chen J, Gu Y (2013) Effects of angiogenic factors, antagonists, and podocyte injury on development of proteinuria in preeclampsia. Reproductive sciences (Thousand Oaks, Calif) 20(5):579–588. doi:10.1177/1933719112459227
24. Park HJ, Kim SH, Jung YW, Shim SS, Kim JY, Cho YK, Farina A, Zanello M, Lee KJ, Cha DH (2014) Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy. BMC Pregnancy Childbirth 14:35
25. Lehnen H, Mosblech N, Reineke T, Puchooa A, Menke-Mollers I, Zechner U, Gembruch U (2013) Prenatal clinical assessment of sFlt-1 (Soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) ratio as a diagnostic tool for preeclampsia, pregnancy-induced hypertension, and proteinuria. Geburtshilfe Frauenheilkd 73(5):440–445
26. Odibo AO, Rada CC, Cahill AG, Goetzinger KR, Tuuli MG, Odibo L, Macones GA, England SK (2013) First-trimester serum soluble fms-like tyrosine kinase-1, free vascular endothelial growth factor, placental growth factor and uterine artery Doppler in preeclampsia. J Perinatol Off J California Perinatal Assoc 33(9):670–674. doi:10.1038/jp.2013.33
27. Villa PM, Hamalainen E, Maki A, Raikkonen K, Pesonen AK, Taipale P, Kajantie E, Laivuori H (2013) Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth 13:110. doi:10.1186/1471-2393-13-110
28. Hanita O, Alia NN, Zaleha AM, Nor Azlin MI (2014) Serum soluble FMS-like tyrosine kinase 1 and placental growth factor concentration as predictors of preeclampsia in high risk pregnant women. Malays J Pathol 36(1):19–26
29. Doherty A, Carvalho JC, Drewlo S, El-Khuffash A, Downey K, Dodds M, Kingdom J (2014) Altered hemodynamics and hyperuricemia accompany an elevated sFlt-1/PlGF ratio before the onset of early severe preeclampsia. J Obstet Gynaecol Canada JOGC J D’obstetrique et gynecologie du Canada JOGC 36(8):692–700
30. Moore Simas TA, Crawford SL, Bathgate S, Yan J, Robidoux L, Moore M, Maynard SE (2014) Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women. J Maternal-Fetal Neonatal Med 27(10):1038–1048
31. Sunderji S, Gaziano E, Wothe D, Rogers LC, Sibai B, Karumanchi SA, Hodges-Savola C (2010) Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 202(1):40.e41-47. doi:10.1016/j.ajog.2009.07.025
32. Stubert J, Ullmann S, Bolz M, Kulz T, Dieterich M, Richter DU, Reimer T (2014) Prediction of preeclampsia and induced delivery at <34 weeks gestation by sFLT-1 and PlGF in patients with abnormal midtrimester uterine Doppler velocimetry: a prospective cohort analysis. BMC Pregnancy Childbirth 14(1):292
33. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. New England J Med 355(10):992–1005. doi:10.1056/NEJMoa055352
34. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE (2007) Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 197(3):244.e241–244.e248. doi:10.1016/j.ajog.2007.06.030
35. Deeks JJ (2001) Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 323(7305):157–162
36. Oudejans CB, van Dijk M, Oosterkamp M, Lachmeijer A, Blankenstein MA (2007) Genetics of preeclampsia: paradigm shifts. Hum Genet 120(5):607–612. doi:10.1007/s00439-006-0259-1
37. Mignini LE, Latthe PM, Villar J, Kilby MD, Carroli G, Khan KS (2005) Mapping the theories of preeclampsia: the role of homocysteine. Obstet Gynecol 105(2):411–425. doi:10.1097/01.AOG.0000151117.52952.b6
38. James JL, Whitley GS, Cartwright JE (2010) Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol 221(4):363–378. doi:10.1002/path.2719
39. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA (2004) Circulating angiogenic factors and the risk of preeclampsia. New England J Med 350(7):672–683. doi:10.1056/NEJMoa031884
40. Karumanchi SA, Lindheimer MD (2008) Preeclampsia pathogenesis: “triple a rating”-autoantibodies and antiangiogenic factors. Hypertension 51(4):991–992. doi:10.1161/HYPERTENSIONAHA.107.100735
41. Gu Y, Lewis DF, Wang Y (2008) Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metabol 93(1):260–266. doi:10.1210/jc.2007-1550
42. Mutter WP, Karumanchi SA (2008) Molecular mechanisms of preeclampsia. Microvasc Res 75(1):1–8. doi:10.1016/j.mvr.2007.04.009